ProRx Pharma Aligns Workforce Expansion with Operational Scale-Up

ProRx Pharma, the leading health and wellness 503B outsourcing facility, announced a period of significant growth, including increased production capacity, a larger facility footprint, and expanded delivery capabilities into two new states, Oklahoma and Virginia, with additional states expected in the coming months.

Over the past several months, ProRx has expanded its physical footprint from approximately 3,400 square feet to approximately 17,000 square feet. The space now includes additional clean rooms and specialized environments for sterile and non-sterile hazardous, and non-hazardous drug production with further buildouts underway.

This expansion has directly supported a significant increase in production output. Monthly production has grown substantially since December, with additional increases expected in the coming months.

"We've tripled production capacity in a relatively short period of time, but that growth is the result of deliberate investment," said Kurt Lunkwitz, chief operating officer at ProRx Pharma. "Our focus has been on building the infrastructure required to scale in a controlled way while maintaining quality and consistency across our operations."

Workforce growth has followed alongside the operational investments with staffing approximately doubling in recent months. ProRx has added pharmacists, quality-control, and operational roles to support increased production demands, along with several corporate support staff in HR and IT.

Looking forward, ProRx is preparing to expand its product portfolio with new injectable preparations that include Testosterone and Estradiol Cypionate, targeted for release in the coming months.